US 7,320,965 B2
Compositions and methods for inhibiting expression of Huntingtin gene
Dinah Wen-Yee Sah, Boston, Mass. (US); Philipp Hadwiger, Altenkunstadt (Germany); Ingo Roehl, Memmelsdorf (Germany); Birgit Bramlage, Kulmbach (Germany); Pamela Tan, Kulmbach (Germany); Hans-Peter Vornlocher, Bayreuth (Germany); and David Bumcrot, Belmont, Mass. (US)
Assigned to Alnylam Pharmaceuticals, Inc., Cambridge, Mass. (US)
Filed on Oct. 27, 2006, as Appl. No. 11/588,674.
Claims priority of provisional application 60/836040, filed on Aug. 07, 2006.
Claims priority of provisional application 60/819038, filed on Jul. 07, 2006.
Claims priority of provisional application 60/731555, filed on Oct. 28, 2005.
Prior Publication US 2007/0099860 A1, May 03, 2007
Int. Cl. A61K 31/70 (2006.01); C07H 21/04 (2006.01); C12Q 1/68 (2006.01); C12P 19/34 (2006.01); C12N 5/00 (2006.01); C12N 5/02 (2006.01)
U.S. Cl. 514—44  [536/23.1; 536/24.3; 536/24.33; 536/24.5; 435/6; 435/91.1; 435/325; 435/375] 8 Claims
OG exemplary drawing
 
1. A double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a human Huntingtin gene in a cell, wherein said dsRNA comprises a sense strand consisting of SEQ ID NO:792 and an antisense strand consisting of SEQ ID NO:793.